baber/WOPTO huggingface dataset:
Patent NZ-574099-A (NZ)
Title: Fuel overflow prevention device whose exit port of the nozzle is arranged to establish a flow restricting fit
Inventor: PETERSON MICHAEL
IPC: B67D7/44
Filed: 2007-06-14
Abstract: Disclosed is a fuel overflow prevention device (10) for use in combination with a fuel storage container (18). The fuel storage container (18) has a fill tube (20), a vent tube (22) and an automatic shutoff fuel nozzle having a spout (14) with a sensor port (16) and an exit port (15). The fuel overflow device (10) includes an overflow prevention chamber (12). The overflow prevention chamber (12) comprises a primary fill space (36), a fill tube interface section (26) and a vent tube interface section (28). The primary fill space (36) is configured for removably receiving the automatic shutoff fuel nozzle (14). The fill tube interface section (26) is configured for releasable attachment to the fill tube (20). The vent tube interface section (28) is configured for releasable attachment to the vent tube (22). The fill tube interface section (26) is further configured to establish a flow restricting fit between the fill tube interface section (26) and the exit port (15) of the nozzle. The flow restricting fit is restrictive enough to minimize fuel flow from within the fill tube (20) into the primary fill space (36). The vent tube interface section (28) is arranged to establish a fluid passageway between the fuel storage container (18) and the primary fill space (36) through the vent tube (22). The primary fill space (36) is arranged to receive enough fluid from the vent tube (22) to cover the sensor port (16) to a level that is sufficient to trigger automatic shutoff of the nozzle.
Patent NZ-575523-A (NZ)
Title: A slide fastener where the puller interacts with the top stop to lock the slider when the fastener is fully closed
Inventor: COSSUTTI LIVIO
IPC: A44B19/30
Filed: 2009-03-13
Abstract: A slide fastener with a lock is disclosed. The fastener (1) comprises a pair of tapes (2) with teeth (3), a top stop (4) and a slider (5). The slider (5) has a puller (6) with is connected to the slider by a ring (7). The fastener (1) is in a closed condition when the slider (5) is in contact with the top stop (4). The top stop (4) has at least one retaining element (20) adapted to retain the slider (5) contact with the top stop (4). The top stop has at least one locking element (22, 23) to retain the puller (6) in a locked position, the at least one locking element (22, 23) being elastically deformable adapted to snap on the ring (7) connecting the puller (6) to the slider (5).
Patent NZ-578717-A (NZ)
Title: Spirocyclic cyclohexane derivatives
Inventor: SCHUNK STEFAN
IPC: A61K31/382
Filed: 2008-02-19
Abstract: Disclosed are 4-alkyl-spiro[cyclohexane-1,1'(1'H)-pyrido[3,4-b]indol]-4-amine derivatives as represented by the general formula (I), wherein R1 and R2 independently of one another represent H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or the radicals R1 and R2 together form a morpholine or piperazine ring system; R3 represents alkyl which may be saturated or unsaturated, branched or unbranched, unsubstituted or substituted by one or more F, Cl, Br, I, CN, NH2, NO2, SH, cyclopentyl, cyclohexyl, CF3, OH, OCH3, OC2H5 or dimethylamino; X represents O, S, SO, SO2 or NR17; and wherein the remaining substituents are as defined herein. Further disclosed is a medicament which comprises at least one spirocyclic cyclohexane derivative as defined above and optionally comprising one or more suitable additives and/or auxiliary substances and/or additional active ingredients for the treatment of one or more of anxiety, stress, depression, epilepsy, Alzheimer's disease, senile dementia, general cognitive dysfunctions, learning and memory disorders, withdrawal symptoms, alcohol and/or drug and/or medicament abuse and/or dependency, sexual dysfunctions, cardiovascular diseases, hypotension, hypertension, tinnitus, pruritus, migraine, impaired hearing, deficient intestinal motility, impaired food intake, anorexia, obesity, locomotor disorders, diarrhoea, cachexia, urinary incontinence or as a muscle relaxant, anticonvulsive or anaesthetic or for co-administration in the case of treatment with an opioid analgesic or with an anaesthetic, for diuresis or antinatriuresis, anxiolysis, for modulation of motor activity, for modulation of neurotransmitter secretion and treatment of one or more neurodegenerative diseases associated therewith, for the treatment of withdrawal symptoms and/or for reducing the addictive potential of one or more opioids.
Patent NZ-585791-A (NZ)
Title: Power acquisition unit configured to acquire electrical power from an external power source for an electronic device
Inventor: SEIL OLIVER DUNCAN
IPC: H04B7/00
Filed: 2005-09-08
Abstract: A power acquisition unit configured to acquire electrical power from an external power source, such as a cigarette lighter, for use with an electronic device, is disclosed. The power acquisition unit, in the form of a cigarette lighter adapter, comprises: (a) one or more electrodes to electrically couple to the external power source and receive electrical power from the external power source; (b) one or more conductors electrically coupled to the one or more electrodes and configured to transmit at least a portion of the power received by the one or more electrodes to the electronic device; (c) a housing with an exterior side and enclosing at least a portion of the one or more conductors; (d) one or more springs coupled to the exterior side of the housing; and (e) a stabilizer, which comprises a deformable resilient member, is mechanically coupled to the exterior side of the housing where the housing is mechanically coupled the one or more electrodes.
Patent NZ-586343-A (NZ)
Title: Nanodispersion comprising taxane derivatives, fatty acids and sterols
Inventor: KHOPADE AJAY JAYSINGH
IPC: A61K31/337
Filed: 2008-12-23
Abstract: Disclosed is a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivatives, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts. Examples of a taxane derivative are paclitaxel and docetaxel. Examples of solvents are alcohols, glycols, polyalkylene glycols, glycerol and glycofurol. Examples of polymers are polyvinylpyrrolidone and polyethylene glycol. Examples of fatty acids are caprylic acid, oleic acid and stearic acid Examples of sterols are cholesterol, cholesteryl esters of polar acids, phytosterols, bile acids. Also disclosed is a solution comprising one or more taxane derivatives, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or salts thereof in a water miscible solvent, which on dilution with an aqueous liquid vehicle gives a nanodispersion.
Patent NZ-588473-A (NZ)
Title: Hydroxyquinoxalinecarboxamide derivative
Inventor: MOTOKI KAYOKO
IPC: C07D401/12
Filed: 2009-03-24
Abstract: Disclosed are hydroxyquinoxalinecarboxamides represented by formula (i) or pharmacologically acceptable salts thereof, wherein the substituents are disclosed within the specification. Also disclosed is the use of the said hydroxyquinoxalinecarboxamides for the manufacture of a medicament for preventing or treating thromboembolism, congential anticoagulant factor deficiency or plasminogen abnormality.
Patent NZ-591255-A (NZ)
Title: Housing for an energy source in a hand-operated device having a mechanism for ejecting the source
Inventor: ALMERAS ROLAND
IPC: F17C13/00
Filed: 2006-04-25
Abstract: The housing is intended to receive à source (20) introduced bó means of its head and pushed into à position ensuring good transmission of energy. The housing includes à mechanism (60,61,62) for converting à transverse movement towards the interior of the housing imparted bó à pusher element (61) of the mechanism accessible from the exterior of the housing into an orthogonal movement for ejection of the source (20).
Patent NZ-593388-A (NZ)
Title: Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
Inventor: FREEMAN GORDON
IPC: A61K39/395
Filed: 2006-06-08
Abstract: A method of assessing effectiveness of a cancer treatment in a subject administered a PD-L1 antagonist, said method comprising: measuring PD-I expression on T cells in a biological sample from the subject ex vivo, wherein a decrease in PD-I expression on the T cells indicates that the PD-L1 antagonist is efficacious for treating cancer.
Patent NZ-594277-A (NZ)
Title: Constant force helical torsion spring system for roller blinds
Inventor: BOHLEN JORG
IPC: E06B9/68
Filed: 2010-02-04
Abstract: Disclosed is a roller blind including a roller of having a roller length and a roller outer diameter, a fabric attached to said roller for winding und unwinding from said roller. The fabric has a fabric length, a fabric weight, a fabric height, and fabric thickness. The blind includes a bottom bar having a bottom bar weight, and at least one spring operatively connected to the roller to drivingly rotate the roller in at least one direction of rotation. The spring is selected according to a Protocol such that it's length ensures that it drives the roller with a constant operating force.
Patent NZ-596475-A (NZ)
Title: Magnetic field detector for indicating tampering in a utility meter
Inventor: PRIDE BRUCE MICHAEL
IPC: G01F1/60
Filed: 2011-11-16
Abstract: Disclosed is a utility service meter (106) having magnetic tampering detection means. The utility service meter includes a magnetic field strength sensor (302), which detects magnetic field (208) strength proximate to the meter (106) and continuously produces an analogue voltage signal proportional to the detected magnetic field (208) strength. This signal is fed into at least one analogue-to-digital converter which converts the analogue voltage signal into a digital voltage signal. Also included are a memory and one or more processors. The one or more processors are configured to intermittently store said digital voltage signal in the memory and monitor the digital voltage signal for an aberration which indicates tampering of the meter (106). The monitoring procedure is performed by determining an average value for the stored digital voltage signals and, if the current digital voltage signal deviates from the average value by some predetermined percentage of the average value, concluding that an aberration exists.
Patent NZ-596933-A (NZ)
Title: Alert system with controlled load of network
Inventor: HEEN KJELL-HARALD
IPC: H04W4/90
Filed: 2010-05-27
Abstract: 596933 A system and a method for preventing overload and blocking of a mobile network when sending of alert messages to a plurality of mobile phone users located in a specific geographical area, and doing so independently of any user preferences on the mobile phones are disclosed. The system comprises an optimizing message distribution component (A-SMSC) (30) connected to the mobile network, and with means for: a) receiving an alert initiation message comprising information about the content of the message and where it is to be sent, represented as relevant cells, and where this is done via a cell coverage component (LBAS GT) (40) with information about geographical area and corresponding cell IDS; b) receiving updated information, from a location based alert system database (LBAS database) (25), of mobile station ISDN (MSISDN) numbers with current serving cells on base station system (BSS) level, c) assessing received information and determine the location the relevant mobile phones with corresponding MSISDN number to send alert messages to. The system further comprises means for: d) placing a prevention tag for the determined relevant mobile phones on MSC/VLR level, where the tag indicates that the mobile phones with corresponding MSISDN numbers that alert messages are going to be sent to are not authenticated when these are trying to initiate a call from the specific geographical area to MSC, and further that external calls to the determined relevant mobile phones are not to be connected; e) sending alert messages from the A-SMSC through a serving MSC to relevant mobile phones with corresponding MSISDN numbers located in the specific geographical area and f) removing placed tags for said relevant mobile phones after finishing the alerting.
Patent NZ-597287-A (NZ)
Title: An inhaler with a flexible diaphragm within a housing defining an air flow path
Inventor: HEARN ALEX
IPC: A24F42/60
Filed: 2010-08-06
Abstract: 597287 Disclosed is an inhaler comprising a reservoir (5) of an inhalable composition. A housing (1) contains the reservoir (5) and has an outlet end (8) and an opposite end. A composition flow path (13) for the flow of the composition extends from the reservoir (5) along the flow path (13) and out of a composition outlet at the outlet end (8) of the housing (1). A flexible diaphragm (16) within the housing (1) defines an air flow path (13) from an air inlet (25) to an air outlet (9) at the outlet end (8) of the housing (1), the diaphragm (16) extending past the air flow inlet (25) towards the opposite end separating the air flow path (13) on one side of the diaphragm (16) from the remainder of the housing (1) on the opposite side of the diaphragm. A valve element (15) is movable with the diaphragm (16).
Patent NZ-598083-A (NZ)
Title: New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
Inventor: DREWES PERNILLE GUNDORF
IPC: A61K9/16
Filed: 2010-08-23
Abstract: Disclosed herein is a pharmaceutical composition for oral administration comprising the compound 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine and pharmaceutically acceptable acid addition salts thereof, wherein said composition is an enteric coated tablet. Also disclosed is the use of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine and pharmaceutically acceptable acid addition salts thereof in the manufacture of a pharmaceutical composition for oral administration for the treatment of a disease selected from mood disorders; major depressive disorder; general anxiety disorder; panic disorder; post-traumatic stress disorder; depression associated with cognitive impairments, Alzheimer's disease or anxiety; depression with residual symptoms; chronic pain; eating disorder or abuse, wherein said composition is a tablet of a multi-particulate composition coated with an enteric coating.
Patent NZ-598180-A (NZ)
Title: Cigarette blank loading apparatus
Inventor: ACCORDINO PHILIP F
IPC: A24C5/00
Filed: 2010-07-15
Abstract: An apparatus for loading a cigarette blank onto a filling tube. The apparatus comprises a filling tube (350) having a first end (351), a second end (352), an inside diameter (353), an outside diameter (354), and a pin (374) sized to fit within the filling tube (350). The pin (374) has a first end and a second end comprising a guide head (370). When the filling tube (350) receives the second end of the pin (374), at least a portion of the guide head (370) of the pin (374) extends beyond the second end (352) of the filling tube (350) for guiding the cigarette blank onto the filling tube (350).
Patent NZ-598530-A (NZ)
Title: Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
Inventor: DOMINGO PEDROL JOAN CARLES
IPC: A23L23/00
Filed: 2006-12-20
Abstract: Disclosed herein is the use of a therapeutic amount of DHA, EPA, or DHA-derived EPA incorporated into a glyceride, wherein said DHA, EPA or DHA derived EPA incorporated into a glyceride is obtained enzymatically; and wherein said DHA, EPA or DHA derived EPA is in a percentage by weight between 40 and 100% in relation to the total fatty acids; or wherein said DHA, EPA or DHA derived EPA is incorporated into an sn-2 position of the glyceride; for the preparation of a medicament for the treatment of a disease selected from a neurodegenerative pathology, an ocular pathology, an ischaemic pathology, an inflammatory process, atherosclerosis; wherein said neurodegenerative pathology may be selected from multiple sclerosis, Alzheimer's disease, Parkinson's disease, amiotrophic lateral sclerosis, and muscular dystrophy; wherein said ocular pathology may be selected from pigmentary retinosis, macular degeneration, and cataracts; wherein said ischaemic pathology may be selected from myocardial infarct and cerebral infarct; and wherein said inflammatory process may be selected from arthritis, vasculitis, glomerulonephritis, eritomatose lupus and also for treating cellular oxidative damage comprising the production of reactive oxygen species (ROS) associated with a physiological condition selected from ageing, physical exercise, hypoglycemia during or after physical exercise.
Patent NZ-610120-A (NZ)
Title: Optical fiber junction box
Inventor: HUBBARD PAUL
IPC: B26F1/00
Filed: 2013-05-02
Abstract: 610120 An optical fibre junction box for installation into a wall is disclosed. The junction box comprises a housing (50) and a cutter (51) provided on a rear side of the housing. The cutter comprises a plurality of cutting teeth formed around a first circumferential edge of a first side of a disc plate. A plurality of spring locking tabs (52) are formed around a second circumferential edge of a second side, which is opposite to the first side, of the disc plate. The disc plate also has a driller centrally fixed on the first side which acts as a centre point about which the cutter rotates. When rotated, the cutter cuts the wall and enters into the wall to embed the housing in the wall. The housing is retained in the wall by the spring locking tabs. A main body portion of the housing (57), which defines a chamber (571) is configured to receive an optical fibre tray (20), on which an optical fibre can be wound.
Patent NZ-622735-A (NZ)
Title: Improved structure of trampoline
Inventor: CHANG WEN-TAI
IPC: A63B71/02
Filed: 2014-03-20
Abstract: Disclosed is a trampoline with a safety net with support legs that deflect resiliently so as to enhance security and safety of the trampoline user. The trampoline comprises a ring-shaped main body, which comprises a plurality of legs extending downwards therefrom. The main body comprises a bed unit arranged therein where the bed unit comprises a mat and a fence. The mat is connected by a plurality of first elastic spring elements to the main body. A plurality of support units are mounted to the main body in such a way that the support units are spaced from each other by a distance. Each of the support units comprises at least one coupling member that is mounted to one of the legs of the main body, at least one second elastic element, and at least one first support bar that is connected by the second elastic element to the coupling member. The fence has a top that is coupled to the first support bar. When the first support bar is compressed and pushed by an external force, the second elastic element provides a reaction force for position restoration of the first support bar. The coupling member of each of the support units is mounted to and projects outward from one of the legs of the main body, the second elastic element having two ends respectively coupled to a lower end of the first support bar and a top of the coupling member. The second elastic element comprises a spring and the first support bar comprises a thread formed on an end thereof for coupling with the second elastic element through screwing engagement.
Patent NZ-623145-A (NZ)
Title: Humanized il-6 and il-6 receptor
Inventor: STEVENS SEAN
IPC: C07K14/715
Filed: 2012-10-29
Abstract: Disclosed is a genetically modified mouse comprising a replacement at an endogenous mouse IL-6 locus of a mouse gene encoding IL-6 with a human gene encoding human IL-6, wherein the human gene encoding human IL-6 is under control of endogenous mouse regulatory elements at the endogenous mouse IL-6 locus. Also disclosed is a genetically modified mouse, comprising a humanisation of an endogenous mouse IL-6Rα gene, wherein the humanisation comprises a replacement of mouse IL-6Rα ectodomain-encoding sequence with human IL-6Rα ectodomain-encoding sequence at the endogenous mouse IL-6Rα locus, and wherein the humanised IL-6Rα gene is under control of endogenous mouse regulatory elements.
Patent NZ-704278-A (NZ)
Title: Large-diameter rotary electric machine rotor and rotary electric machine
Inventor: CASAZZA MATTEO
IPC: H02K7/18
Filed: 2013-07-25
Abstract: A rotor (3) of a wind turbine large-diameter rotary electric machine (1) has a hub (4) designed to rotate about an axis of rotation (A); a tubular structure (25) extending about the hub (4) and supporting a plurality of active segments (6) arranged about the axis of rotation (A); and a radial structure (7) for connecting the hub (4) to the tubular structure (25), which is divided into a plurality of sectors connectable selectively to the radial structure (7).
Patent NZ-711657-A (NZ)
Title: Cftr mrna compositions and related methods and uses
Inventor: GUILD BRAYDON
IPC: A61K31/7105
Filed: 2014-03-14
Abstract: Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.
Patent NZ-716154-A (NZ)
Title: Tricyclic benzoxaborole compound, preparation method therefor, and use thereof
Inventor: IM WEON-BIN
IPC: C07F5/04
Filed: 2014-07-28
Abstract: The present invention relates to (7-methyl-7,8-dihydro-2H-1,6,9-trioxa-9a-borabenzo[cd]azulen-2-yl)methanamine and its stereoisomers, a preparation method thereof, and an antibiotic pharmaceutical composition comprising the same as an active ingredient.
Patent NZ-724877-A (NZ)
Title: Ang2 antibodies
Inventor: LEUNG DONMIENNE DOEN MUN
IPC: C07K16/22
Filed: 2015-05-12
Abstract: The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
Patent NZ-734916-A (NZ)
Title: Chimeric antigen receptors targeting b-cell maturation antigen
Inventor: GALETTO ROMAN
IPC: C07K16/28
Filed: 2016-03-30
Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).